TSPO has been shown to be a robust and sensitive biomarker for microglial activation in neurodegenerative conditions [30] and increased TSPO levels in PET were found in the progression of mild cognitive impairment and Alzheimer’s disease [31,32]. This evidence concerns the gene TSPO and early-onset autosomal dominant Alzheimer disease.